deltatrials
Completed PHASE1 NCT00003282

EF5 in Treating Patients With Solid Tumors

Phase I Trial of EF5, an Agent for the Detection of Hypoxia

Sponsor: National Cancer Institute (NCI)

Conditions Unspecified Adult Solid Tumor, Protocol Specific
Interventions EF5 biopsy pharmacological study therapeutic conventional surgery
Updated 6 times since 2017 Last updated: Jan 15, 2013 Started: Mar 31, 1998 Primary completion: May 31, 2005

This PHASE1 trial investigates Unspecified Adult Solid Tumor, Protocol Specific and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Philadelphia, United States